SELLAS Life Sciences Group, Inc.
SLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001390478
No open-market purchases or sales by SELLAS Life Sciences Group, Inc. insiders were filed in the last 90 days; 193 institutions reported holding it in 13F filings for Q2 2026, worth $1.08B in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding SELLAS Life Sciences Group, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 22 | 25 | +3 |
| Shares | 3.00M | 3.13M | +130.9K (+4.4%) |
| Value | $4.28M | $4.91M | +$623.9K (+14.6%) |
New holders (7)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Prosperity Financial Group, Inc. | 29,800 | $46.8K | 0.04% |
| Susquehanna International Group, LLP | 15,462 | $24.3K | 0.00% |
| Independent Financial Group, LLC | 12,650 | $19.9K | 0.00% |
| Commonwealth Equity Services, LLC | 12,414 | $19.0K | 0.00% |
| Nemes Rush Group LLC | 10,000 | $15.7K | 0.00% |
| Citadel Advisors LLC | 3,162 | $4.96K | 0.00% |
| JPMorgan Chase & Co | 2,000 | $3.14K | 0.00% |
Sold out (4)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Dimensional Fund Advisors LP | 31,304 | $44.8K |
| Price T Rowe Associates Inc | 17,100 | $25.0K |
| Values First Advisors, Inc. | 15 | $21 |
| WealthPLAN Partners, LLC | 1 | $1 |